Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

The Top 5 Biosimilar Articles for the Week of May 5

May 9th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of May 5, 2025.

Targeted Reimbursement Encourages Oncology Biosimilar Use

May 7th 2025

By Skylar Jeremias

Article

Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.

Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow

May 6th 2025

By Cameron Santoro

Article

Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.

BioRationality: A New Bill to Transform the Future of Biosimilars

May 5th 2025

By Sarfaraz K. Niazi, PhD

Article

Escaping the Void: All Things Biosimilars With Craig & G

May 4th 2025

By Craig Burton

Podcast

To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."

Future Directions for Ustekinumab Biosimilars in Crohn Disease

May 3rd 2025

By Deana Ferreri, PhD

Article

The Top 5 Biosimilar Articles for the Week of April 28

May 2nd 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of April 28, 2025.

Samsung Bioepis Report Signals Turning Point for US Biosimilars

May 1st 2025

By Skylar Jeremias

Article

A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.

Biosimilars Policy Roundup: April 2025

April 30th 2025

By Skylar Jeremias

Article

Between congressional hearings and executive orders, experts had plenty to draw on when dissecting the barriers to biosimilar access at Festival of Biologics USA to close out April 2025.

Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships

April 29th 2025

By Skylar Jeremias

Article

Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.